id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-323293-4gmnkg09	Sobhani, Navid	Mutant p53 as an Antigen in Cancer Immunotherapy	2020-06-08		.txt	text/plain	7906	416	51	To corroborate such a possibility, a recent study showed that a T cell receptor-like (TCLR) antibody, initially made for a wild-type antigen, was capable of discriminating between mutant p53 and wild-type p53, specifically killing more cancer cells expressing mutant p53 than wild-type p53 in vitro and inhibiting the tumour growth of mice injected with mutant p53 cancer cells than mice with wild-type p53 cancer cells. The accumulation of the p53-mut protein could, in turn, induce circulating p53 antibodies (p53-Abs) in cancer patients [76, 77] . Furthermore, in lung cancer, there are controversies regarding the clinical utility of s-p53-Abs. In fact, in non-small-cell lung carcinoma (NSCLC) the antibodies are associated with worse survival [130] [131] [132] . Although our review showed that, in most of cases the presence of s-p53-Abs correlated with worse survival, it would be interesting to investigate whether p53 antibodies recognize p53 hotspot mutations, including c.659A > G (p.Y220C) and c.733G > A (p.G245S), which have been uniquely discovered in human ovarian cancers [161] .	./cache/cord-323293-4gmnkg09.txt	./txt/cord-323293-4gmnkg09.txt